Case Number 112039 - Sensitive & Non-Invasive Assay to Monitor Residual and Recurrent Tumors in Glioblastoma multiforme patients

Contact: Jill Uhl
Phone: 513-558-5621

Description:  Dr. El Mustapha Bahassi has developed a sensitive and non-invasive assay to detect epidermal growth factor receptor III (EGFRvIII, the most common form of mutant EGFR) mutations in the circulating DNA of brain tumor patients. EGFRvIII is a truncated extracellular mutant of the EGF receptor found in about a third of glioblastoma multiformes. Currently, numerous anti-EGFRvIII therapies are in development. However, no biomarker diagnostics are available to monitor their efficacy.

Dr. Bahassi’s innovative assay solves this unmet need. Utilizing personalized biomarkers that detect all possible EGFRvIII deletions, the assay is able to accurately monitor residual and recurrent tumors and enhance the clinical management of GBM patients.

The technology has the following advantages over currently available tests:

A provisional patent is pending.